COR Cencora
Data as of close
Industrials · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cencora (COR) is an industrial company in the Wholesale-Drugs, Proprietaries & Druggists' Sundries industry, with a market capitalization of $64.5 billion. Shares last traded at $337.91, 10.5% below their 52-week high. Over the past year the stock is down 1.0%. COR trades at a price-to-earnings ratio of 24.57, below the Wholesale-Drugs, Proprietaries & Druggists' Sundries median of 24.96. Net profit margin is 0.8%, above the peer median of 0.7%. Revenue grew 9.3% year over year. The shares yield 0.7% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
COR Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-09-30 | $437M | $2.24 | 28% |
| 2024-09-30 | $416M | $2.08 | 28% |
| 2023-09-30 | $399M | $1.95 | 23% |
| 2022-09-30 | $392M | $1.85 | 23% |
| 2021-09-30 | $367M | $1.76 | 24% |
| 2020-09-30 | $344M | $1.68 | — |
| 2019-09-30 | $339M | $1.60 | 40% |
| 2018-09-30 | $333M | $1.51 | 20% |
| 2017-09-30 | $320M | $1.45 | 88% |
| 2016-09-30 | $288M | $1.28 | 20% |
| 2015-09-30 | $254M | $1.17 | — |
| 2014-09-30 | $214M | $0.91 | 78% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q3 2026 | $3.94 | 2026-08-05 |
| Q2 2026 | $8.40 | 2026-05-06 |
| Q1 2026 | $2.87 | 2026-02-04 |
| Q4 2025 (derived) | -$1.74 | 2025-11-25 |
| FY 2025 | $7.96 | 2025-11-25 |
| Q3 2025 | $3.52 | 2025-08-06 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Wholesale-Drugs, Proprietaries & Druggists' Sundries peers
COR vs 9 industry peers (Wholesale-Drugs, Proprietaries & Druggists' Sundries), by market cap. Data as of close
| MCK | McKesson Corporation | $116.4B | 25.36 | 0.28 | 1.1% | +0.30% |
| COR | Cencora | $64.5B | 24.57 | 0.19 | 0.8% | +2.11% |
| CAH | Cardinal Health | $59.2B | 35.59 | 0.24 | 0.7% | +1.53% |
| HLF | Herbalife Ltd. | $1.4B | 7.75 | 0.26 | 3.4% | +1.68% |
| NUS | NU SKIN ENTERPRISES, INC. | $233M | — | 0.17 | -15.7% | +2.36% |
| COSM | Cosmos Health Inc. | $31M | — | 0.42 | -33.1% | -0.70% |
| ESYN | HWH International Inc. | $13M | — | — | — | -6.42% |
| MEDS | DataMeds AI, Inc. | $5M | — | — | — | -8.25% |
| HKPD | Cellyan Biotechnology Co., Ltd | $2M | — | — | — | -12.74% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.